PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2015
CASE
AUTH/2750/3/15 GlaxoSmithKline

AUTH/2750/3/15: Actelion v GlaxoSmithKline (Volibris) β€” interaction charts and β€œeducational grant” wording (No breach)

Actelion challenged two GSK Volibris leavepieces: an ERA drug–drug interaction table and a Stockley’s interaction chart described as funded by an β€œeducational…

2014
CASE
AUTH/2734/9/14 Boehringer Ingelheim

AUTH/2734/9/14: Head of Prescribing Support Unit v Boehringer Ingelheim (Striverdi Respimat) – cycling imagery not misleading (No breach)

A pharmacist challenged a Striverdi Respimat leavepiece showing an older woman cycling, alleging the artwork overstated likely COPD benefit. The PMCPA Panel…

2014
CASE
AUTH/2720/6/14 Genzyme

AUTH/2720/6/14: Anonymous v Genzyme β€” discussion of Aubagio monitoring requirements (no breach)

Anonymous complaint alleged a Genzyme employee suggested monthly (off-licence) liver monitoring for Aubagio. Accounts conflicted and evidence was insufficient; the Panel ruled…

2014
CASE
AUTH/2702/3/14 Pfizer ⭐ Case of the Week

AUTH/2702/3/14: General Practitioner v Pfizer β€” remote detailing access via call scheduling (no breach)

A GP alleged a Pfizer representative used subterfuge and urgency to get through to him via reception. The Panel found the call…

2013
CASE
AUTH/2659/11/13 Pfizer

AUTH/2659/11/13: Member of the public v Pfizer β€” Clinical trial disclosure (Conbriza and Xiapex) (No breach after appeal)

Public complaint about alleged late/non-disclosure of trial results for Conbriza and Xiapex. Panel initially found breaches for Xiapex, but Appeal Board ruled…

2016
CASE
AUTH/2835/4/16 Janssen

AUTH/2835/4/16: Janssen voluntary admission over outdated Invokana prescribing information email (No breach)

A mailing agency resent an older Invokana promotional email to GPs with outdated prescribing information. Janssen self-reported, but the Panel ruled no…

2015
CASE
AUTH/2805/12/15 Guerbet Laboratories

AUTH/2805/12/15: Bayer v Guerbet β€” contrast injector β€œloan” deals and Clause 2 discredit

Bayer alleged Guerbet offered CT/MRI contrast injectors as gifts/long-term loans tied to contrast spend. Panel found no breach of Clause 18.1 (no…

2015
CASE
Ferring Pharmaceuticals

Ferring voluntary admission: sales manager drafted hospital letter to GPs promoting DesmoMelt over Desmospray (disguised promotion)

Ferring admitted a sales manager drafted text for hospital consultants to send to GPs recommending DesmoMelt and discouraging Desmospray. Even though no…

2016
CASE
AUTH/2911/11/16 Galen ⭐ Case of the Week

AUTH/2911/11/16: Anonymous (non-contactable) v Galen β€” Promotion of Laxido (No breach)

Anonymous complaint about alleged misleading cost-saving claims, rebates and competitor disparagement in Laxido promotion at a Scottish Prescribers Association meeting. Panel found…

2016
CASE
AUTH/2865/8/16 Sanofi

AUTH/2865/8/16: Anonymous (non-contactable) v Sanofi β€” MEGS nurse advisor service via consultancy company (No breach)

Anonymous complaint alleged industry-funded audits/workshops and coercive behaviour linked to prescribing. Panel found no evidence against Sanofi; its MEGS nurse advisor service…

2012
CASE
Roche Products

Roche: delayed clinical trial results disclosure for BP22572 (Kadcyla/Perjeta) due to misclassification

PMCPA found Roche failed to disclose results of a Phase Ib/IIa trial (BP22572) within required timelines due to internal phase misclassification. Breach…

2017
CASE
AUTH/2931/1/17 Pfizer

Pfizer β€˜Ultimate Stop Smoking Roadshow’ invite: sponsorship clear, but β€˜ultimate’ breached professional standing (AUTH/2931/1/17)

Pulse online ad and emails invited HCPs to a Pfizer-funded stop smoking roadshow. Panel found sponsorship clear and no PI required on…

2016
CASE
AUTH/2923/12/16 Merck Sharp & Dohme

Merck Sharp & Dohme: Remicade ad strapline β€œmore than a name” implied special merit without substantiation (AUTH/2923/12/16)

A hospital pharmacist challenged a Remicade journal ad using a dandelion image and the strapline β€œmore than a name”. Appeal Board found…

2017
CASE
AUTH/2988/10/17 Otsuka ⭐ Case of the Week

Employee v Otsuka (AUTH/2988/10/17): LinkedIn posts promoted POMs to the public and included pre-licence and off-label content

An Otsuka employee used a personal LinkedIn account to share links about tolvaptan and brexpiprazole. The Panel found promotion of POMs to…

2007
CASE
AUTH/2009/6/07 Flynn Pharma

AUTH/2009/6/07: Anonymous v Flynn Pharma β€” Promotion of Medikinet (No breach)

Anonymous complaint about allegedly inappropriate Medikinet mailings, rep calls, and a German clinical paper. Panel found targeting to child psychiatrists/paediatricians reasonable and…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training